Clinical Trials on Hereditary Melanoma

Total 5802 results

University Medical Center Groningen

Not yet recruiting

Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG (MelanooMSOT)

Melanoma Stage III | Melanoma, Stage II | Melanoma, Stage I
Yonsei University

Not yet recruiting

Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor

Mucosal Melanoma | Acral Melanoma

Korea, Republic of
Eye & ENT Hospital of Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM (SNMM)

Mucosal Melanoma | Sinonasal Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma (JS001)

Metastatic Melanoma | Unresectable Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China
Ichor Medical Systems Incorporated
Memorial Sloan Kettering Cancer Center

Completed

Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

Intraocular Melanoma | Melanoma (Skin)

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study for Patients With Stage IV Melanoma

Metastatic Melanoma | Stage IV Melanoma

United States
Hoffmann-La Roche

Completed

Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies

Malignant Melanoma, Cancer

Hungary
Hoffmann-La Roche

Completed

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Malignant Melanoma, Neoplasms

United States, South Africa, Croatia, Brazil, Egypt
Lynn E. Spitler, MD
Genentech, Inc.; Celgene Corporation

Completed

Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study (AbraxAvast)

Metastatic Malignant Melanoma

United States
Delcath Systems Inc.
IQVIA Biotech

Completed

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma (FOCUS)

Melanoma, Ocular

United States, Spain, Italy, Germany, United Kingdom, Switzerland, Belgium, Austria, France
Jonsson Comprehensive Cancer Center

Completed

Cytogenetic Study of Ocular Melanoma

Choroidal Melanoma

United States
San Diego Pacific Oncology & Hematology Associates

Unknown

Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma

Intraocular Melanoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Recurrent Melanoma | Stage IV Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Centre Hospitalier Universitaire de Nice

Unknown

Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ) (MALT)

Malignant Melanoma Stage III | Malignant Melanoma Stage IV
The Christie NHS Foundation Trust
University of Liverpool; University of Manchester; Manchester Academic Health...

Terminated

Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION (DETECTION)

Melanoma (Skin) | Melanoma, Stage II

United Kingdom
Hasumi International Research Foundation

Active, not recruiting

IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma

Melanoma, Uveal Metastatic

Germany
Hoffmann-La Roche

Completed

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

Malignant Melanoma, Neoplasms

Korea, Republic of, Brazil, United States, Canada, Cyprus
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Spain, New Zealand, Hungary, Serbia, Germany, Portugal, Netherlands, Greece, Australia
IDEAYA Biosciences

Recruiting

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Colorectal Cancer | Metastatic Uveal Melanoma | Cutaneous Melanoma | Other Solid Tumors

United States, Australia, Canada
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage IIIc Melanoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Melanoma | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Terminated

Tanespimycin in Treating Patients With Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Dr. Ronnie Shapira

Not yet recruiting

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma (MK3475-C01)

Metastatic Melanoma | Malignant Melanoma | Immunotherapy | Malignant Melanoma Stage IV | BRAF V600E
Elizabeth Davis
Bristol-Myers Squibb

Terminated

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

Metastatic Melanoma | Advanced Melanoma | Metastatic Melanoma Stratified by MHC-II Expression

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. (NILOMEL)

Stage IV Melanoma | Stage III Melanoma | Amplification | Malignant Skin Melanoma T0

France
MelanomaPRO, Russia
Novartis

Recruiting

pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE (RATIONALE)

Melanoma | Melanoma Stage IV | Melanoma Stage III

Russian Federation
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Malignant Melanoma Stage III

Austria, Netherlands, Australia, Sweden
Eisai Inc.
PharmaBio Development Inc.

Completed

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Stage IV Melanoma | Stage IIIC Melanoma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Withdrawn

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Melanoma Stage IV | Melanoma Stage III

United States
Immutep Australia Pty. Ltd.

Completed

Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma (TACTI-mel)

Stage IV Melanoma | Stage III Melanoma

Australia
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Terminated

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

Melanoma | Malignant Melanoma | Melanoma, Experimental

United States
Mannkind Corporation

Terminated

Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

Stage IV Melanoma | Stage III Melanoma

United States
Steinar Aamdal

Terminated

Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

Metastatic Malignant Melanoma

Norway
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Melanoma | Acral Melanoma | Mucosal Lentiginous Melanoma

United States
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Belgium, Spain, Germany, Netherlands, Finland
Eli Lilly and Company

Completed

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Metastatic Malignant Melanoma

United States
National Cancer Institute (NCI)

Terminated

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma

United States
Perspective Therapeutics

Recruiting

MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma

Metastatic Melanoma | Melanoma (Skin) | Mucosal Melanoma | Melanoma Stage IV | Melanoma Stage III | Melanoma, Uveal

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)

United States
National Cancer Institute (NCI)

Completed

Lovastatin in Treating Patients At High Risk of Melanoma

Precancerous Condition | Stage II Melanoma | Stage 0 Melanoma | Stage I Melanoma

United States
Regina Elena Cancer Institute

Recruiting

Versatile Ampification Single-Molecule Detection in Liquid Biopsy (VerSiLiB)

Melanoma (Skin) | Liquid Biopsy | Melanoma Stage IV | Melanoma Stage III | BRAF V600E

Italy
Universitair Ziekenhuis Brussel

Recruiting

A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma (RegoMel)

Melanoma Stage IV | Melanoma Stage III

Belgium
Evaxion Biotech A/S
Merck Sharp & Dohme LLC

Recruiting

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Melanoma Stage IV | Melanoma Stage III

Australia
The Netherlands Cancer Institute

Recruiting

FMT to Convert Response to Immunotherapy

Melanoma Stage IV | Melanoma Stage III

Netherlands
University of California, San Francisco
Array BioPharma

Recruiting

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Melanoma Stage IV | Melanoma Stage III

United States
Kelly McMasters

Recruiting

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Melanoma Stage IV | Melanoma Stage III

United States
Pierre Fabre Pharma GmbH
Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment (BERING)

Melanoma Stage IV | Melanoma Stage III

Austria, Germany, Switzerland

Clinical Trials on Hereditary Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations